Commentary

The prevalence of online banners and text ads have made all but the most annoying online ads nearly transparent to online users, reports Tech/Know columnist Troy Janisch. To stand out from the crowd, he writes that some marketers are turning to a simple, relevant, and...

With apologies to Mark Twain, rumors of the death of online advertising have been greatly exaggerated, according to Buzz Networks columnist Paul Gibler. Thanks to new and creative ways to drive online advertising, Gibler says it has been resurrected and is well on its way...

Wisconsin is leaving money on the table by not fully developing its academic R&D potential, argues columnist Tom Still, and changing that means more support for research outside of Madison and Milwaukee. In this edition of Inside Wisconsin, Still highlights the biofuel work of University...

Our innovation is fueled by the strength of the U.S. patent system, yet there is a movement to erode the very system that is driving entrepreneurialism, according to Jim Greenwood, president and CEO of BIO, which will hold its Mid-America VentureForum this month in Milwaukee....

Many economists fear that the flat world, as defined by author and New York Times columnist Thomas Friedman, has led us to the brink of a global bubble, a bit more ominous than the dotcom bubble, according to columnist Tom Koulopoulos. In this WTN debut...

Outsourcing and China have made headlines over the past 12 months, and not in a positive way. High profile product recalls of items such as toys, toothpaste, and food are highlighting the risks of sourcing products globally, particularly to countries where quality and safety standards...

In the age of dumb and dumber, the United States needs more dynamic leadership in public education if it intends to maintain and build the knowledge-based economy and compete in global markets, asserts columnist James Carlini. In this edition of Carlini's Comments, he laments recent...

The Midwest has scored some impressive gains in the nanotechnology area, including the second largest (after TomoTherapy) initial public offering in the Midwest and the luring of a star nanotech researcher away from UCLA. Whether or not that holds the promise of whittling away the...